Cargando…
New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2
The Bcl-2 protein has been studied as an anticancer drug target in recent years, due to its gatekeeper role in resisting programmed cancer cell death (apoptosis), and the design of BH3 domain mimetics has led to the clinical approval of Venetoclax (ABT-199) for the treatment of chronic lymphocytic l...
Autores principales: | Hamdy, Rania, Elseginy, Samia A., Ziedan, Noha I., Jones, Arwyn T., Westwell, Andrew D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479519/ https://www.ncbi.nlm.nih.gov/pubmed/30986908 http://dx.doi.org/10.3390/molecules24071274 |
Ejemplares similares
-
Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2
por: Hamdy, Rania, et al.
Publicado: (2020) -
New Bioactive Fused Triazolothiadiazoles as Bcl-2-Targeted Anticancer Agents
por: Hamdy, Rania, et al.
Publicado: (2021) -
Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors
por: Almehdi, Ahmed M., et al.
Publicado: (2023) -
Combretastatin-Inspired Heterocycles as Antitubulin
Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018) -
Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases
por: Elseginy, Samia A., et al.
Publicado: (2021)